Study S001626

A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT02057172
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 254
Start: 2014-01
Primary completion: 2014-10
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Type 2 Diabetes
Interventions: DRUG:HM11260C; DRUG:liraglutide; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks [Up to 127 days]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009458	Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide. Rosenstock J, Diabetes care	2019	Randomized trial	PMID 31320446 DOI	cites ClinicalTrials.gov:NCT02057172; registry reference DERIVED:31320446
R0047817	1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes? GEORGE E. DAILEY, Diabetes	2019	Other	DOI	cites ClinicalTrials.gov:NCT02057172
R0050116	1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203 Julio Rosenstock, Diabetes	2019	Other trial	DOI	cites ClinicalTrials.gov:NCT02057172